Mutation News and Research

RSS

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS).

21 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

Study explores genetic imbalances that give rise to childhood brain tumors

The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.

21 May 2010

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

21 May 2010

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Parents found to be carriers of a mutated form of the tumor suppressor genes known as BRCA1 and BRCA2 do not always share these test results with their children, but they may choose to discuss related information important to their own health with them. That is the result of a study conducted by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues, whose findings suggest that those parents are using the discovery of their mutation status as an opportunity for a "teachable moment" in educating their offspring about cancer risk reduction.

21 May 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.

21 May 2010

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology annual meeting in Chicago.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New study uses NMR in drug design

A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.

20 May 2010

Mutation in BRCA1 tumor suppressor gene helps develop breast, ovarian cancer: Study

Studies have well established that women who harbor a mutation in the BRCA1 tumor suppressor gene are at greater risk for developing breast and ovarian cancers. Less known is information on other molecular events that may impact cancer formation in cells having a BRCA1 mutation. Investigators from The Cancer Institute of New Jersey and a number of major cancer centers in Europe have identified the role a key protein plays in helping cells with mutant BRCA1 genes to survive.

20 May 2010

Gene therapy shows positive effects in rat models of PAH: Researchers

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension, according to researchers at the University of Adelaide in Australia.

20 May 2010

Experimental evolution used to develop new strains of bacteria for use as probiotic substances

When the forces of evolution took over an experimental strain of bacteria, it derailed an experiment Duke and NC State researchers thought they were conducting, but led to something much more profound instead.

19 May 2010

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.

19 May 2010

Study results may help researchers determine genetic abnormalities that cause lung disease to develop

Patients who encounter serious lung diseases in middle age, despite an absence of family history or other predisposing factors, may still have their genes to blame, according to a new study conducted by researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

19 May 2010

AmbryScreen test launched to identify severe childhood diseases

Ambry Genetics announced today at the American College of Obstetricians and Gynecologists annual clinical meeting the launch of AmbryScreen, a genetic screening test used to identify carriers of some of the most severe and common childhood diseases affecting pan-ethnic populations.

19 May 2010

WHO Director-General pushes for sustained commitment to MDGs at World Health Assembly

During her opening address to the World Health Assembly in Geneva, Switzerland, on Monday, WHO Director-General Margaret Chan called for increased global efforts to reach the Millennium Development Goals, PANA/Afrique en ligne reports. Chan also set-up several global health challenges to be addressed during the five-day meeting, according to the news service.

19 May 2010

Population Diagnostics receives NINDS grant for identifying genetic causes of Parkinson's Disease

Population Diagnostics, Inc. ("PDx"), a private company with a novel approach to revealing the genetic causes of disease and predicting drug response, announced today it has been awarded a federal grant to identify the genetic causes of Parkinson's Disease. Funded by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health, the project is being led by Eli Hatchwell, MD, PhD, an Associate Professor at Stony Brook University Medical Center and a co-founder of PDx.

18 May 2010

Ambry Genetics launches AmbryScreen test for genetic screening of severe, common childhood diseases

Ambry Genetics announced today at the American College of Obstetricians and Gynecologists annual clinical meeting the launch of AmbryScreen™, a genetic screening test used to identify carriers of some of the most severe and common childhood diseases affecting pan-ethnic populations.

18 May 2010

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, demonstrating that the personalized immunotherapy has a positive impact on the genetic diversity of residual HIV virus, and also results in substantially increased time to viral rebound in HIV patients treated with AGS-004 following antiretroviral therapy (ART) interruption.

17 May 2010

Scientists find clues to how our brains work

Scientists from The Scripps Research Institute have found a specific chemical compound secreted by many predators that makes mice behave fearfully. The research helps scientists better understand animal behavior, and may eventually lead to new insights into how sensory information is processed in human brains.

17 May 2010

Mutation News and Research

IGF1 drug improves nerve cell communication in PMS mouse model

European researchers define research priorities in biogerontology

Study explores genetic imbalances that give rise to childhood brain tumors

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

New study uses NMR in drug design

Mutation in BRCA1 tumor suppressor gene helps develop breast, ovarian cancer: Study

Gene therapy shows positive effects in rat models of PAH: Researchers

Experimental evolution used to develop new strains of bacteria for use as probiotic substances

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Study results may help researchers determine genetic abnormalities that cause lung disease to develop

AmbryScreen test launched to identify severe childhood diseases

WHO Director-General pushes for sustained commitment to MDGs at World Health Assembly

Population Diagnostics receives NINDS grant for identifying genetic causes of Parkinson's Disease

Ambry Genetics launches AmbryScreen test for genetic screening of severe, common childhood diseases

Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR

Scientists find clues to how our brains work

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News